Assessment time points a | Study day 2 | Study day 30 | Study day 58 | Study day 86 | |||||
---|---|---|---|---|---|---|---|---|---|
Study | Fluralaner | Control | Fluralaner | Control | Fluralaner | Control | Fluralaner | Control | |
1 | Meanb tick counts (n) | 1.8 (3.8) | 20.5 (25.1) | 0 (0) | 29.1 (29.8) | 0 (0) | 32.6 (32.9) | 0 (0) | 33.8 (34.0) |
Count range (n) | 0–19 | 4e–44 | 0 | 20–39 | 0 | 26–39 | 0 | 29–39 | |
Efficacyc (%) | 91.1 (84.9) d | 100 (100) d | 100 (100) d | 100 (100) d | |||||
P-value | 0.0004 | < 0.0001 | < 0.0001 | < 0.0001 | |||||
2 | Meanb tick counts (n) | 0 (0) | 18.7 (19.9) | 0 (0) | 13.8 (16.5) | 0 (0) | 24.7 (26.3) | 0.1 (0.1) | 34.2 (35.8) |
Count range (n) | 0 | 10f–34 | 0 | 3f–34 | 0 | 16–37 | 0–1 | 26–67 | |
Efficacy c (%) | 100 (100) d | 100 (100) d | 100 (100) d | 100 (100) d | |||||
P-value | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | |||||
3 | Meanb tick counts (n) | 0 (0) | 10.4 (14.3) | 0 (0) | 24.3 (25.5) | 0 (0) | 15.7 (17.9) | 0 (0) | 19.8 (23.3) |
Count range (n) | 0 | 4g–37 | 0 | 14–38 | 0 | 6g–26 | 0 | 6g–35 | |
Efficacy c (%) | 100 (100) d | 100 (100) d | 100 (100) d | 100 (100) d | |||||
P-value | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | |||||
4 | Meanb tick counts (n) | 0.9 (2.8) | 37.4 (38.6) | 0 (0) | 26.1 (27.7) | 0.2 (0.3) | 18.1 (19.6) | 0.6 (1.1) | 19.4 (20.8) |
Count range (n) | 0–23 | 24–51 | 0 | 16–41 | 0–2 | 8h–33 | 0–5 | 12h–32 | |
Efficacy c (%) | 97.6 (92.7) d | 100 (100) d | 98.9 (98.5) d | 96.7 (94.7) d | |||||
P-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | |||||
5 | Meanb tick counts (n) | 0.7 (1.8) | 21.1 (25.0) | 0 (0) | 26.4 (26.9) | 0 (0) | 28.8 (29.8) | 0.1 (0.1) | 22.3 (23.1) |
Count range (n) | 0–11 | 2i–40 | 0 | 19–37 | 0 | 18–43 | 1–0 | 13–33 | |
Efficacy c (%) | 96.6 (92.8) d | 100 (100) d | 100 (100) d | 99.7 (99.6) d | |||||
P-value | ≤ 0.001 | ≤ 0.001 | ≤ 0.001 | ≤ 0.001 | |||||
6 | Meanb tick counts (n) | 0.1 (0.1) | 30.4 (30.8) | 0.1 (0.1) | 24.0 (24.5) | 0.1 (0.1) | 17.6 (18.7) | 0.0 (0.0) | 17.8 (18.3) |
Count range (n) | 0–1 | 21–38 | 0–1 | 18–31 | 0–1 | 12j–33 | 0 | 11j–25 | |
Efficacy c (%) | 99.8 (99.7) d | 99.7 (99.6) d | 99.6 (99.5) d | 100 (100) d | |||||
P-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 |